Olutasidenib for Leukemia
Trial Summary
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor to get a clear answer based on your specific situation.
Farnesyltransferase inhibitors (FTIs), which are similar to Olutasidenib, have shown promise in treating various blood cancers, including leukemias and myelodysplastic syndromes (MDS). In clinical trials, FTIs have demonstrated the ability to reduce cancerous cells in the bone marrow and improve patient outcomes.
12345Olutasidenib has been studied for safety in patients with acute myeloid leukemia and myelodysplastic syndrome. Common serious side effects include febrile neutropenia (fever with low white blood cell count), anemia (low red blood cell count), thrombocytopenia (low platelet count), and neutropenia (low white blood cell count). Differentiation syndrome, a potentially serious condition, occurred in some patients, with a few severe cases and one fatality reported.
678910Olutasidenib is unique because it is an oral drug specifically designed to target and inhibit the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, which is often found in certain types of leukemia. This targeted approach can lead to durable remissions and transfusion independence in patients with relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation.
6781112Eligibility Criteria
This trial is for patients with IDH1 mutated AML, MDS, or CMML who have had a donor hematopoietic cell transplant. It's designed to see if the drug olutasidenib can prevent their disease from coming back.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Acute Myeloid Leukemia (AML) with a susceptible IDH1 mutation